Group 1 - The stock of TaiLing Pharmaceutical (01011.HK) has dropped over 25% [1] - The company's total market capitalization has reached 290 million HKD [1]

Group 1 - The stock of TaiLing Pharmaceutical experienced a significant decline of nearly 26% in the afternoon session after an early surge of over 31% in the morning [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 表 明 概 不 會 就 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 吳鐵先生 | | 截 至2023年 | 截 至2024年 | | --- | --- | --- | | | 12月31日止年度 | 12月31日止年度 | | | （未 經 審 核） | （未 經 審 核） | | | 人民幣元 | 人民幣元 | | 收 入 | 2,437,639 | 1,810,151 | | 除稅前虧損 | 1,930,143 | 3,049,543 | | 除稅後虧損 | 1,907,899 | 3,068,549 | | 年末負債淨額 | 1,205,370 | 1,863,179 | – 1 – 除 上 述 澄 清 外，該 公 告 中 的 所 有 其 他 資 料 維 持 不 變。 承董事會命 中國泰凌醫藥集團有限公司 主 席 （於開曼群島註冊成立之有限公司） （股 ...

Group 1 - The Hong Kong innovative drug sector experienced an initial rise, with TaiLing Pharmaceutical increasing by nearly 7% [1] - Stone Pharmaceutical saw a rise of over 4% [1] - Other companies such as BeiGene, Zai Lab (603127), and WuXi Biologics also reported gains [1]

Group 1 - The core point of the article is that TaiLing Pharmaceutical (01011.HK) saw a nearly 14% increase in its stock price following the announcement of a new share issuance to acquire an artificial intelligence medical business, involving an investment of 120 million yuan [1] Group 2 - The company is actively expanding its portfolio by integrating artificial intelligence into its medical operations, indicating a strategic move towards innovation in healthcare [1] - The investment of 120 million yuan reflects the company's commitment to enhancing its technological capabilities and staying competitive in the rapidly evolving medical industry [1] - The significant stock price increase suggests positive market sentiment regarding the company's future growth prospects following this acquisition [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 表 明 概 不 會 就 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 本 公 告 僅 供 參 考 之 用，並 不 構 成 收 購、購 買 或 認 購 本 公 司 任 何 證 券 之 邀 請 或 要 約。 （於開曼群島註冊成立之有限公司） （股份代號：1011） 有關涉及根據特別授權發行代價股份之 收購目標公司100%已發行股份之主要交易 收購事項 董 事 會 欣 然 宣 佈，於2025年4月28日，本 公 司（作 為 買 方）與 賣 方 訂 立 買 賣 協 議，據 此，買 方 有 條 件 同 意 購 買 而 賣 方 有 條 件 同 意 出 售 目 標 公 司100%已 發 行 股 份，代 價 為 人 民 幣116,219,960元（相 當 於 約123,638,256港 元），將 以 配 發 及 發 行 代 價 股 份 支 付。 代 價 股 份 將 根 據 股 ...

Financial Performance - The total revenue for the year ended December 31, 2024, was RMB 37,960,000, compared to RMB 7,366,000 for the previous year, representing a significant increase[3] - The gross profit for the year was RMB 5,260,000, down from RMB 7,366,000 in 2023, indicating a decline in profitability[3] - The loss from continuing operations before tax for the year was RMB 53,480,000, compared to a loss of RMB 33,369,000 in the previous year, reflecting a worsening financial position[3] - The net loss for the year was RMB 53,357,000, compared to RMB 143,590,000 in 2023, showing an improvement in overall losses[4] - The group reported a net loss from continuing operations of approximately RMB 53,357,000 for the year ending December 31, 2024[16] - The company reported a loss per share from continuing operations of RMB 20.20, compared to RMB 14.04 in the previous year[4] - The group reported a loss before tax of RMB 53,480 thousand for the year ending December 31, 2024, primarily due to general and administrative expenses[25] - The total comprehensive loss attributable to the company's owners for the year ending December 31, 2024, was RMB 53.4 million, compared to RMB 33.5 million in the previous year, with a basic and diluted loss per share of RMB 20.20[84] Assets and Liabilities - The total assets as of December 31, 2024, were RMB 725,065,000, an increase from RMB 665,087,000 in 2023[5] - The total liabilities as of December 31, 2024, were RMB 399,108,000, compared to RMB 339,565,000 in the previous year, indicating an increase in financial obligations[5] - As of December 31, 2024, the group's current liabilities and total liabilities were approximately RMB 708,880,000 and RMB 399,108,000, respectively[16] - The total borrowings of the group amounted to approximately RMB 375,488,000, with RMB 22,335,000, RMB 313,810,000, and RMB 31,350,000 being overdue and required to be repaid[16] - The group's cash and bank balances totaled approximately RMB 9,623,000 as of December 31, 2024[16] - The group has a financial guarantee obligation for two outstanding loans amounting to approximately RMB 177,008,000 owed to its former subsidiaries as of December 31, 2024[16] Business Operations and Strategy - The company has undergone a change in its principal place of business, effective May 29, 2024, moving to a new location in Hong Kong[6] - The group aims to develop into a comprehensive platform enterprise covering health product supply and health check services, integrating medical equipment and rehabilitation therapy[18] - The group has successfully negotiated with existing lenders to avoid immediate repayment of overdue principal and interest on loans[23] - The group is actively seeking new financing sources or strategic capital investments within the next twelve months[23] - The company plans to focus on the orthopedic market, leveraging its core capabilities to create a comprehensive health platform integrating pharmaceuticals, cross-border e-health, AI medical devices, and medical services[74] - The company has completed a business restructuring, transitioning from heavy asset operations to a light asset model, while actively enhancing cost control[75] - The company has successfully sold and restructured all major assets and traditional businesses, including factories and R&D centers, to focus on its core business[76] Joint Ventures and Investments - The group's share of net assets in the joint venture was RMB 312,960,000 as of December 31, 2023, which is now reclassified as financial assets at fair value through profit or loss[36] - The joint venture reported a revenue of RMB 185,808,000 for the year ending November 30, 2024, down from RMB 304,258,000 in the previous year[40] - The net profit for the joint venture for the same period was RMB 40,494,000, compared to RMB 146,453,000 in the previous year, indicating a significant decline[40] - The group has lost significant influence over Beijing Kangchen Biological Technology Co., Ltd. as of November 30, 2024, and will no longer participate in its board or financial decisions[38] - The group has reclassified its investment in Beijing Kangchen Biological from a joint venture to financial assets at fair value due to the loss of influence[38] Cash Flow and Financing - Net cash generated from operating activities for the period was RMB 20,852,000[61] - Net cash used in investing activities amounted to RMB (2,481,000)[61] - Net cash generated from financing activities was RMB 8,638,000[61] - The company has entered into a subscription agreement to issue 410,156,509 new shares to repay part of its outstanding loans and release financial guarantee contracts[73] - The company completed a placement of 263,073,000 new shares at a price of HKD 0.05 per share, raising a net amount of approximately HKD 12 million for business development[103] Legal and Compliance - The independent auditor was unable to express an opinion on the consolidated financial statements due to significant uncertainties regarding the company's ability to continue as a going concern[120] - The company has engaged specialized legal counsel to protect its litigation rights[109] - Legal claims against the company amount to approximately RMB 24,455,000 for overdue promotional service fees, with additional related costs of about RMB 12,000[104] Employee and Management - The total cost of employee compensation, benefits, and social security for the group was RMB 6.1 million for the year ending December 31, 2024, compared to RMB 3.6 million in 2023[110] - The group employed 22 full-time employees as of December 31, 2024, an increase from 16 full-time employees in 2023[110] - The board of directors currently consists of two executive directors, two non-executive directors, and three independent non-executive directors, with independent non-executive directors making up 43% of the board[114] Shareholder Information - The company did not declare or recommend any dividends for the year[66] - The board does not recommend the payment of a final dividend for the year ending December 31, 2024[116] - The company has proposed a share consolidation, merging every ten shares into one, effective from July 3, 2024, reducing the total issued shares from 2,640,895,000 to 264,089,500[71]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負責， 對其準 確性 或完整 性亦不 發表 任何聲 明，並 明確 表示概 不就因 本公 告全 部 或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：1011） 有關董事會會議召開日期之 澄清公告 茲提述本公司於二零二五年三月十九日所刊發的董事會會議召開日期的公告（「公 告」），除另有界定外，本公告所用的詞彙與公告所界定者具有相同涵義。 該公告「於二零二五年三月三十一日（星期一）舉行董事會會議」一段中，英文版本的 「星期一」由於翻譯過程中的書寫錯誤，誤列為「星期四」。該公告中文版本及英文版 本的其他內容無任何變動。 承董事會命 中 國 泰 淩 醫 藥 集 團 有 限 公 司 吳鐵 主席 香港，2025 年3 月20 日 於本公告日期，執行董事為吳鐵先生及吳靜美女士；非執行董事為錢唯博士及 錢 余女士；及獨立非執行董事為余梓山先生、趙玉彪博士及吳銘軍先生。 – 1 – ...

吳鐵 （股份代號：1011） 董事會會議召開日期 中國泰凌醫藥集團有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將 於二零二五年三月三十一日（星期一）舉行董事會會議，以（其中包括）批准刊發本公 司及其附屬公司截至二零二四年十二月三十一日止年度之全年業績。 承董事會命 中 國 泰 淩 醫 藥 集 團 有 限 公 司 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負責， 對其準 確性 或完整 性亦不 發表 任何聲 明，並 明確 表示概 不就因 本公 告全 部 或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） 主席 香港，2025 年3 月19 日 於本公告日期，執行董事為吳鐵先生及吳靜美女士；非執行董事為錢唯博士及 錢 余女士；及獨立非執行董事為余梓山先生、趙玉彪博士及吳銘軍先生。 – 1 – ...

FF305 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 01011 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | | 庫存股份數目 | | | | | 於下列日期開始時的結存(註1) | 2025年2月1日 | | 264,089,506 | | 0 | | | 264,089,506 | | 1). 其他 (請註明) | | | 410,156,509 | 0 % | 0 | | | | | 經 2025 年 2 月 17 日舉行之股東 ...